0000000001237610

AUTHOR

Christopher E. Brightling

showing 10 related works from this author

Exploring the relevance and extent of small airways dysfunction in asthma (ATLANTIS): baseline data from a prospective cohort study

2019

BACKGROUND: Small airways dysfunction (SAD) is well recognised in asthma, yet its role in the severity and control of asthma is unclear. This study aimed to assess which combination of biomarkers, physiological tests, and imaging markers best measure the presence and extent of SAD in patients with asthma.METHODS: In this baseline assessment of a multinational prospective cohort study (the Assessment of Small Airways Involvement in Asthma [ATLANTIS] study), we recruited participants with and without asthma (defined as Global Initiative for Asthma severity stages 1-5) from general practices, the databases of chest physicians, and advertisements at 29 centres across nine countries (Brazil, Chi…

Pulmonary and Respiratory MedicineSpirometrymedicine.medical_specialtySocio-culturaleSettore MED/10 - Malattie Dell'Apparato RespiratorioDISEASE03 medical and health sciences0302 clinical medicineQuality of lifeHYPERRESPONSIVENESSInternal medicineSeverity of illnessMedicine030212 general & internal medicineProspective cohort studyAsthmamedicine.diagnostic_testbusiness.industryasthmamedicine.diseaseNitrogen washoutrespiratory tract diseasessmall airways dysfunctionLUNG-MECHANICSSEVERITY030228 respiratory systemSalbutamolVENTILATION HETEROGENEITYbiomarkerAsthma; small airways dysfunctionbusinessmedicine.drugCohort study
researchProduct

WITHDRAWN: Scaling up strategies of the Chronic Respiratory Disease programme of the European Innovation Partnership on Active and Healthy Ageing (Ac…

2017

Gerontologymedicine.medical_specialtybusiness.industryRespiratory diseaseAlternative medicinemedicine.disease03 medical and health sciences0302 clinical medicine030228 respiratory systemGeneral partnershipAction planmedicineGeneral Earth and Planetary Sciences030212 general & internal medicineHealthy ageingbusinessGeneral Environmental ScienceAlergologia Polska - Polish Journal of Allergology
researchProduct

Reductions in Inflammatory Biomarkers in Patients with Oral Corticosteroid-Dependent Asthma Treated with Tezepelumab

2021

medicine.medical_specialtybusiness.industrymedicine.drug_classInternal medicineMedicineCorticosteroidIn patientbusinessmedicine.diseaseInflammatory biomarkersGastroenterologyAsthmaTP10. TP010 CLINICAL AND POPULATION-LEVEL STUDIES OF ASTHMA
researchProduct

Global Initiative for Asthma (GINA) Strategy 2021 - Executive summary and rationale for key changes

2021

Funder: Global Initiative for Asthma

ExacerbationRespiratory SystemINHALED CORTICOSTEROIDSCritical Care and Intensive Care MedicineAsthma managementSINGLE-INHALERDOUBLE-BLINDRisk Factorsimmune system diseasesAdrenal Cortex HormonesRELIEVER THERAPYFormoterol FumarateMedicine and Health SciencesImmunology and AllergyAnti-Asthmatic AgentsChild11 Medical and Health SciencesLung functionMILD PERSISTENT ASTHMAExecutive summaryBiologic therapiesCombined Modality TherapyLUNG-FUNCTIONChild PreschoolPractice Guidelines as TopicPerspectiveDisease ProgressionDrug Therapy Combinationmedicine.drugPulmonary and Respiratory MedicineAdultmedicine.medical_specialtyBUDESONIDE/FORMOTEROL MAINTENANCEAdolescentMild asthmaMEDLINEInhaled corticosteroidsCONTROLLED-TRIALSkills trainingGINA Strategy 2021: Executive SummaryBUDESONIDE-FORMOTEROLAdministration InhalationmedicineHumansasthma preventionIntensive care medicineSEVERE EXACERBATIONSAsthmaasthma diagnosisbusiness.industryPatient AcuityInfantasthmamedicine.diseaseAsthmarespiratory tract diseasesSelf Carewf_140Formoterolwf_100businessasthma management
researchProduct

Severe Chronic Allergic (and Related) Diseases: A Uniform Approach – A MeDALL – GA<sup>2</sup>LEN – ARIA Position Paper

2012

Concepts of disease severity, activity, control and responsiveness to treatment are linked but different. Severity refers to the loss of function of the organs induced by the disease process or to the occurrence of severe acute exacerbations. Severity may vary over time and needs regular follow-up. Control is the degree to which therapy goals are currently met. These concepts have evolved over time for asthma in guidelines, task forces or consensus meetings. The aim of this paper is to generalize the approach of the uniform definition of severe asthma presented to WHO for chronic allergic and associated diseases (rhinitis, chronic rhinosinusitis, chronic urticaria and atopic dermatitis) in …

medicine.medical_specialtybusiness.industryPublic healthImmunologymacromolecular substancesGeneral MedicineAtopic dermatitismedicine.disease3. Good health03 medical and health sciences0302 clinical medicine030228 respiratory systemDisease severityEpidemiologyImmunologymedicinePhysical therapyImmunology and AllergyPosition paperDisease process030212 general & internal medicineIntensive care medicinebusinessChronic urticariaAsthmaInternational Archives of Allergy and Immunology
researchProduct

ARIA digital anamorphosis: Digital transformation of health and care in airway diseases from research to practice: Review

2020

Submitted by (omml@ubi.pt) on 2021-07-05T10:37:14Z No. of bitstreams: 1 2021_Bousquet J_A_Anamorphosis.pdf: 1897974 bytes, checksum: 918eb581ab4e940b055ef8514f960e28 (MD5) Approved for entry into archive by Pessoa (pfep@ubi.pt) on 2021-07-05T11:16:44Z (GMT) No. of bitstreams: 1 2021_Bousquet J_A_Anamorphosis.pdf: 1897974 bytes, checksum: 918eb581ab4e940b055ef8514f960e28 (MD5) Approved for entry into archive by Pessoa (pfep@ubi.pt) on 2021-07-05T11:20:07Z (GMT) No. of bitstreams: 1 2021_Bousquet J_A_Anamorphosis.pdf: 1897974 bytes, checksum: 918eb581ab4e940b055ef8514f960e28 (MD5) Made available in DSpace on 2021-07-05T11:20:07Z (GMT). No. of bitstreams: 1 2021_Bousquet J_A_Anamorphosis.pdf: …

0301 basic medicineAllergyCARATComputer scienceIMPACTRespiratory Medicine and Allergy[SDV]Life Sciences [q-bio]computer.software_genreMedical and Health SciencesChange management (ITSM)Rhinitis.0302 clinical medicineQUALITY-OF-LIFEHDE ALERImmunology and AllergyLungmedicin och allergiSelf-managementRhinitis AllergicMultimediaAnamorphosisMOBILE TECHNOLOGYWORK PRODUCTIVITYdigital transformation of health and care3. Good healthsmernice ARIAAirway disease1107 ImmunologyGA(2)LENLife Sciences & BiomedicineASTHMA MULTIMORBIDITYe-zdravje600 Technik Medizin angewandte Wissenschaften::610 Medizin und Gesundheit::610 Medizin und GesundheitARIA; asthma; CARAT; digital transformation of health and care; MASK; rhinitisSEASONAL ALLERGIC RHINITISMASKProcess (engineering)digital transformation of healthcareEUROPEAN INNOVATION PARTNERSHIPImmunologydigitalizacija zdravstvaARIA guidelines61003 medical and health sciencesQuality of life (healthcare)rhinitisHumansMobile technologyddc:610SELF-MANAGEMENTudc:616.2Science & TechnologyARIADigital transformationasthmaRespiration DisordersRhinitis AllergicMODEL030104 developmental biology030228 respiratory system3121 General medicine internal medicine and other clinical medicinee-healthClinical Medicinecomputer
researchProduct

Treating severe asthma:Targeting the IL‐5 pathway

2021

Abstract Severe asthma is a heterogeneous disease with different phenotypes based on clinical, functional or inflammatory parameters. In particular, the eosinophilic phenotype is associated with type 2 inflammation and increased levels of interleukin (IL)‐4, IL‐5 and IL‐13). Monoclonal antibodies that target the eosinophilic inflammatory pathways (IL‐5R and IL‐5), namely mepolizumab, reslizumab, and benralizumab, are effective and safe for severe eosinophilic asthma. Eosinophils threshold represents the most indicative biomarker for response to treatment with all three monoclonal antibodies. Improvement in asthma symptoms scores, lung function, the number of exacerbations, history of late‐o…

0301 basic medicineImmunologyReview ArticleDisease03 medical and health scienceschemistry.chemical_compound0302 clinical medicineReslizumabEosinophilicHumansImmunology and AllergyMedicineInvited ReviewsAnti-Asthmatic AgentsInterleukin 5Asthmabusiness.industryAnti-Asthmatic Agents Asthma Eosinophils Interleukin-5medicine.diseaseBenralizumabAsthmaEosinophils030104 developmental biology030228 respiratory systemchemistryImmunologyBiomarker (medicine)Interleukin-5businessMepolizumabmedicine.drug
researchProduct

Allergic Rhinitis and its Impact on Asthma (ARIA) Phase 4 (2018): Change management in allergic rhinitis and asthma multimorbidity using mobile techn…

2019

Allergic Rhinitis and its Impact on Asthma (ARIA) has evolved from a guideline by using the best approach to integrated care pathways using mobile technology in patients with allergic rhinitis (AR) and asthma multimorbidity. The proposed next phase of ARIA is change management, with the aim of providing an active and healthy life to patients with rhinitis and to those with asthma multimorbidity across the lifecycle irrespective of their sex or socioeconomic status to reduce health and social inequities incurred by the disease. ARIA has followed the 8-step model of Kotter to assess and implement the effect of rhinitis on asthma multimorbidity and to propose multimorbid guidelines. A second c…

AllergyAllergy:Medicina Básica [Ciências Médicas]asthma -- guidelineAllergic asthmaDECISION-MAKINGAllergic Rhinitis and Its Impact on AsthmaGUIDELINESMedical and Health SciencesMedical Records0302 clinical medicineHealth careImmunology and Allergy030212 general & internal medicineAllergic Rhinitis and Its Impact on Asthma; asthma; Change management; rhinitis; Immunology and Allergy; ImmunologyMASK-RHINITISComputingMilieux_MISCELLANEOUSRinitismobilne aplikacijeupravljanje spremembMedical recordGLOBAL STRATEGYWORK PRODUCTIVITYTelemedicinemobile applications3. Good healthAsma alérgicarhiniti1107 ImmunologyCiências Médicas::Medicina Básicaklinične potiallergic -- guidelineLife Sciences & BiomedicineHumanPATIENT PARTICIPATIONAllergic RhinitisTelemedicinemedicine.medical_specialtyanimal structuresmultimorbidityEUROPEAN INNOVATION PARTNERSHIPImmunologyChange Management[object Object]Settore MED/10 - Malattie Dell'Apparato RespiratorioAsthma/diagnosisCHRONIC DISEASESMACVIA-ARIA03 medical and health sciencesrhinitismedicinemultimorbidnostQUALITYHumanscritical pathwaysastma -- smernicaPatient participationAsmaudc:616.2AsthmaScience & TechnologyARIAbusiness.industryAllergic Rhinitis and Its Impact on Asthma; asthma; Change management; rhinitis; Change Management; Humans; Medical Records; Asthma; Multimorbidity; Rhinitis Allergic; TelemedicineSettore MED/09 - MEDICINA INTERNAchange managementMultimorbidityMobile Airways Sentinel Network (MASK) Study GroupGuidelineasthmata3121medicine.diseaseRinite alérgicaRhinitis AllergicRhinitis Allergic/diagnosisAsthmaIntegrated carealergijski rinitis -- smernicaAllergic Rhinitis and Its Impact on Asthma asthma Change management rhinitis Immunology and Allergy Immunology030228 respiratory systemFamily medicine3121 General medicine internal medicine and other clinical medicineMedical RecordClinical Medicinebusiness[SDV.MHEP]Life Sciences [q-bio]/Human health and pathologyImpact on AsthmaJournal of Allergy and Clinical Immunology
researchProduct

Efficacy and safety of tralokinumab in patients with severe uncontrolled asthma: a randomised, double-blind, placebo-controlled, phase 2b trial

2015

Summary Background Interleukin 13 is a central mediator of asthma. Tralokinumab is a human interleukin-13 neutralising monoclonal antibody. We aimed to assess the efficacy and safety of two dosing regimens of tralokinumab in patients with severe uncontrolled asthma. Methods We did a randomised, double-blind, placebo-controlled, parallel-group, multicentre, phase 2b study at 98 sites in North America, South America, Europe, and Asia. Patients aged 18–75 years with severe asthma and two to six exacerbations in the previous year were randomly assigned (1:1), via an interactive voice-response or web-response system, to one of two dosing regimen groups (every 2 weeks, or every 2 weeks for 12 wee…

Pulmonary and Respiratory Medicineeducation.field_of_studyPediatricsmedicine.medical_specialtyExacerbationbusiness.industryPopulationPlacebomedicine.diseaselaw.inventionRandomized controlled trialTolerabilitylawMedicineSalmeteroleducationbusinessTralokinumabmedicine.drugAsthmaThe Lancet Respiratory Medicine
researchProduct

Cabbage and fermented vegetables: from death rate heterogeneity in countries to candidates for mitigation strategies of severe COVID-19

2021

International audience; Large differences in COVID-19 death rates exist between countries and between regions of the same country. Some very low death rate countries such as Eastern Asia, Central Europe, or the Balkans have a common feature of eating large quantities of fermented foods. Although biases exist when examining ecological studies, fermented vegetables or cabbage have been associated with low death rates in European countries. SARS-CoV-2 binds to its receptor, the angiotensin-converting enzyme 2 (ACE2). As a result of SARS-CoV-2 binding, ACE2 downregulation enhances the angiotensin II receptor type 1 (AT1 R) axis associated with oxidative stress. This leads to insulin resistance …

ARIA groupAntioxidantMediterranean dietmedicine.medical_treatmentBrassicasulforaphaneMESH: Angiotensin-Converting Enzyme 2ReviewcabbageAntioxidants0302 clinical medicine10183 Swiss Institute of Allergy and Asthma ResearchVegetableskimchiFood sciencekimči0303 health sciencesMESH: NF-E2-Related Factor 23. Good healthAngiotensin-converting enzyme 22723 Immunology and Allergyfermentirana zelenjavaMESH: EcologyKeywords: Angiotensin converting enzyme 2NF-E2-Related Factor 2KEAP1-NRF2 SYSTEMImmunologyReviewsBrassicaNRF203 medical and health sciencesudc:578:635.34:663.15:COVID‐19angiotensin-converting enzyme 2CorrespondenceHumansMESH: SARS-CoV-2LactobacilluINTERMITTENT HYPOXIA2403 ImmunologyScience & TechnologyMESH: HumansAngiotensin II receptor type 1koronavirusMESH: Antioxidantsmedicine.disease030228 respiratory systemchemistryFermentationAllergymedicine.disease_causechemistry.chemical_compoundLINKING GUT MICROBIOTALactobacillalesLactobacillusImmunology and AllergyMESH: COVID-19Angiotensin converting enzyme 2030212 general & internal medicineOXIDATIVE STRESS[SDV.IMM.ALL]Life Sciences [q-bio]/Immunology/AllergologyKeywords: Angiotensin converting enzyme 2; COVID-19; Lactobacillus; cabbage; diet; fermented vegetable; kimchi; sulforaphane.angiotensin-converting enzyme 2; cabbage; COVID-19; diet; fermented vegetable; kimchi; Lactobacillus; sulforaphane2. Zero hungerFOODSEcologyLactobacillalesMortality rate10177 Dermatology ClinicMEDITERRANEAN DIET1107 ImmunologyLife Sciences & Biomedicinefermented vegetable610 Medicine & healthSettore MED/10 - Malattie Dell'Apparato RespiratorioBiologyMESH: FermentationMESH: Gastrointestinal MicrobiomeInsulin resistanceMESH: DietDownregulation and upregulationmedicine030304 developmental biologySARS-CoV-2COVID-19MESH: BrassicaCOVID-19; Lactobacillus; angiotensin-converting enzyme 2; cabbage; diet; fermented vegetable; kimchi; sulforaphane; Angiotensin-Converting Enzyme 2; Antioxidants; COVID-19; Diet; Ecology; Gastrointestinal Microbiome; Humans; Lactobacillales; NF-E2-Related Factor 2; Brassica; Fermentation; SARS-CoV-2; Vegetablesbiology.organism_classificationMESH: VegetablesDYSFUNCTIONDietGastrointestinal MicrobiomeLactobacillusMESH: Lactobacillalesangiotensin-converting enzyme 2 cabbage COVID-19 diet fermented vegetable kimchi Lactobacillus sulforaphanedietOxidative stressSulforaphane
researchProduct